323,443 Shares in ANI Pharmaceuticals, Inc. $ANIP Purchased by Deutsche Bank AG

Key Points

• Deutsche Bank acquired 323,443 shares of ANI Pharmaceuticals during the second quarter, valued at approximately $26.8 million and representing about 1.42% of the company. Institutional investors collectively own 76.05% of ANIP.
• ANI Pharmaceuticals exceeded quarterly expectations, reporting $2.21 in EPS versus the $2.04 consensus and revenue of $266.04 million, up 25.8% year over year. The company also issued fiscal 2026 EPS guidance of $9.19–$9.69.
• Shares opened at $75.35, well below the 52-week high of $99.50. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $105.83, although several firms recently lowered targets or downgraded their ratings.

Deutsche Bank AG acquired a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 323,443 shares of the specialty pharmaceutical company's stock, valued at approximately $26,775,000. Deutsche Bank AG owned about 1.42% of ANI Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Rice Hall James & Associates LLC acquired a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $2,364,000. Persistent Asset Partners Ltd acquired a new stake in shares of ANI Pharmaceuticals during the second quarter worth about $76,000. State of Wyoming purchased a new position in shares of ANI Pharmaceuticals in the second quarter valued at approximately $86,000. Walleye Capital LLC acquired a new position in shares of ANI Pharmaceuticals in the second quarter valued at approximately $8,784,000. Finally, Pacer Advisors Inc. grew its holdings in shares of ANI Pharmaceuticals by 6.9% in the first quarter. Pacer Advisors Inc. now owns 85,467 shares of the specialty pharmaceutical company's stock valued at $6,572,000 after purchasing an additional 5,548 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, Director Thomas Haughey sold 2,000 shares of the company's stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.88, for a total value of $161,760.00. Following the transaction, the director directly owned 38,878 shares of the company's stock, valued at $3,144,452.64. This represents a 4.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the business's stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00. Following the completion of the sale, the vice president directly owned 74,424 shares of the company's stock, valued at $5,617,523.52. The trade was a 0.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 18,987 shares of company stock valued at $1,546,405. 8.10% of the stock is owned by company insiders.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $75.35 on Friday. ANI Pharmaceuticals, Inc. has a one year low of $70.15 and a one year high of $99.50. The company has a market cap of $1.73 billion, a P/E ratio of 16.24 and a beta of 0.44. The business has a fifty day moving average of $80.36 and a two-hundred day moving average of $78.88. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. During the same period in the previous year, the firm earned $1.80 EPS. The business's revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ANIP shares. Guggenheim reduced their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a report on Monday, August 10th. Canaccord Genuity Group reduced their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating on the stock in a report on Monday, August 10th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Zacks Research cut shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 14th. Finally, Weiss Ratings downgraded shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $105.83.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source